Skip to main content
Fig. 5 | Clinical and Translational Allergy

Fig. 5

From: Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months

Fig. 5

Changes in abundance levels expressed as the natural logarithm of the score fold change (ln[T36/T0]) for periostin in omalizumab responders (OR) and non-omalizumab responders (NOR) at baseline (T0) and after 36 months (T36) of anti-IgE treatment. A negative value indicates a decrease in periostin at T36; a positive value indicates an increase in periostin at T36. OR and NOR are classified according to whether they experienced a reduction in RBM thickness (OR) or no reduction in RBM thickness (NOR) after 12 months of anti-IgE treatment

Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us